Cutter & CO Brokerage, Inc. Galectin Therapeutics Inc Transaction History

Cutter & CO Brokerage, Inc.

$406 Million
Q3 2024

A detailed history of Cutter & CO Brokerage, Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Cutter & CO Brokerage, Inc. holds 115,488 shares of GALT stock, worth $137,430. This represents 0.08% of its overall portfolio holdings.

Number of Shares

115,488

Previous 115,488 -0.0%

Holding current value

$137,430

Previous $261,000 21.46%

% of portfolio

0.08%

Previous 0.07%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$2.13 - $4.2 $61 - $121	29 Added 0.03%	115,488 $261,000
Q1 2024 Apr 30, 2024	SELL	$1.6 - $2.44 $3,246 - $4,950	-2,029 Reduced 1.73%	115,459 $275,000
Q4 2023 Feb 01, 2024	SELL	$1.6 - $2.18 $19,200 - $26,160	-12,000 Reduced 9.27%	117,488 $195,000
Q4 2022 Feb 03, 2023	SELL	$1.03 - $1.66 $41,292 - $66,549	-40,090 Reduced 23.64%	129,488 $146,000
Q1 2022 May 03, 2022	SELL	$1.61 - $2.31 $22,345 - $32,060	-13,879 Reduced 7.57%	169,578 $273,000
Q4 2021 Feb 10, 2022	SELL	$2.07 - $3.8 $2,659 - $4,883	-1,285 Reduced 0.7%	183,457 $380,000
Q2 2020 Aug 10, 2020	BUY	$1.66 - $3.15 $306,671 - $581,937	184,742 New	184,742 $565,000
Q1 2020 May 05, 2020	SELL	$1.51 - $3.0 $134,752 - $267,720	-89,240 Closed	0 $0
Q2 2019 Jul 31, 2019	BUY	$3.61 - $5.0 $117,108 - $162,200	32,440 Added 57.11%	89,240 $370,000
Q1 2019 Apr 23, 2019	SELL	$3.86 - $6.02 $3,860 - $6,020	-1,000 Reduced 1.73%	56,800 $290,000
Q4 2018 Feb 07, 2019	BUY	$3.43 - $5.74 $4,459 - $7,462	1,300 Added 2.3%	57,800 $198,000
Q3 2018 Oct 12, 2018	BUY	$3.68 - $6.93 $9,200 - $17,325	2,500 Added 4.63%	56,500 $340,000
Q2 2018 Jul 30, 2018	BUY	$3.16 - $9.16 $1,264 - $3,664	400 Added 0.75%	54,000 $343,000
Q1 2018 May 11, 2018	BUY	$3.78 - $5.97 $39,690 - $62,685	10,500 Added 24.36%	53,600 $254,000
Q4 2017 Jan 30, 2018	SELL	$1.54 - $3.34 $17,710 - $38,410	-11,500 Reduced 21.06%	43,100 $144,000
Q3 2017 Oct 23, 2017	SELL	$1.67 - $2.3 $3,340 - $4,600	-2,000 Reduced 3.53%	54,600 $117,000
Q2 2017 Aug 07, 2017	BUY	N/A	56,600	56,600 $139,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.65M

Call Options Held

1.16M

Put Options Held

1.98M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $70.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutter & CO Brokerage, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cutter & CO Brokerage, Inc. with notifications on news.

Account

Cutter & CO Brokerage, Inc. Galectin Therapeutics Inc Transaction History